Hepatology:CCR2/CCR5抑制剂—CVC可减轻酒精诱导的脂肪肝性肝炎和肝损伤

2018-09-25 MedSci MedSci原创

CCR2/CCR5抑制剂—CVC可减轻酒精诱导的脂肪肝性肝炎和肝损伤。

库弗氏细胞(KC)和巨噬细胞(MO)激活导致酒精性肝病(ALD)的脂肪变性、炎症和纤维化。研究发现,在ALD患者的肝脏中,MO,T细胞和Ccr2和Ccr5的表达频率增加了;在酒精性肝炎患者中循环趋化因子、CCL2和CCL5等表达增加。研究假设,采用双CCR2/5抑制剂—cenicriviroc(CVC)抑制CCL2信号,将会减弱ALD。

研究方法和结果:在小鼠ALD模型中,无论是在整个酒精喂养过程中作为“预防”,还是在ALD的发展之后开始“治疗”后,肝损伤(ALT)和脂肪变性均被CVC所抑制。在CVC预防或治疗模型中,酒精诱导的早期肝纤维化标志物(天狼星红, ?羟(基)脯氨酸和 I型胶原)的增加被降为正常水平。研究发现,CVC的“预防”和“治疗”逆转了与酒精相关的肝脏TNFalpha、IL-1beta、IL-6和CCL mRNA和蛋白质表达的增加。

在酒精喂养的小鼠中,CVC的治疗或预防阻止了浸润性MO (F4/80(lo) CD11b(hi) )和减少了促炎Ly6C(H)(i) MO的数量。CVC增加了肝T细胞数量和减弱了Il-2表达,对CD69(+)或CD25(+)T细胞的表达没有影响。在体内,CVC抑制了肝细胞内CCL2-诱导的Fasn和Adrp等水平的增加,同时增加了Acox-1、Pgc1alpha和Ucp-2的表达,展示了减轻肝细胞脂肪变性的机制。研究同时发现CCL2和CCL5使肝细胞对LPS导致的肝损害更加敏感(TNFalpha,ALT和LDH释放)。在肝脏中,酒精喂养导致细胞凋亡(PARP和caspase-3)和细胞死亡(gasdermin D);CVC 阻止了这两种细胞死亡形式。

研究结论:CCR2/CCR5抑制剂—CVC可减轻酒精诱导的脂肪肝性肝炎和肝损伤。

原始出处

Ambade A, Lowe P, Kodys K, et al. Pharmacological inhibition of CCR2/5 signaling prevents and reverses alcohol-induced liver damage, steatosis and inflammation in mice.Hepatology, 2018, Sep 4. doi: 10.1002/hep.30249.

本文系梅斯医学(MedSci)原创编译整理,转载需授权!

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (6)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1851793, encodeId=126c1851e93c0, content=<a href='/topic/show?id=f0a254918f0' target=_blank style='color:#2F92EE;'>#抑制剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54918, encryptionId=f0a254918f0, topicName=抑制剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=44a360, createdName=jklm09, createdTime=Wed May 08 15:54:00 CST 2019, time=2019-05-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1977730, encodeId=6c2919e7730c2, content=<a href='/topic/show?id=4b7d4230bd' target=_blank style='color:#2F92EE;'>#CCR2#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4230, encryptionId=4b7d4230bd, topicName=CCR2)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=08e4137, createdName=meichuangyi, createdTime=Sun May 12 22:54:00 CST 2019, time=2019-05-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1338791, encodeId=a2ac1338e9190, content=<a href='/topic/show?id=9d3d812280b' target=_blank style='color:#2F92EE;'>#肝损伤#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=81228, encryptionId=9d3d812280b, topicName=肝损伤)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=198d2500149, createdName=12498bd5m16暂无昵称, createdTime=Thu Sep 27 09:54:00 CST 2018, time=2018-09-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1397630, encodeId=e4d0139e6308e, content=<a href='/topic/show?id=8bee565436d' target=_blank style='color:#2F92EE;'>#损伤#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=56543, encryptionId=8bee565436d, topicName=损伤)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/DYAIOgq83eoNX3lUOlDKGBUEPNwZx0nibmdcFyeibnX4WMhUSCU2REpGRWtSmnT2CCs0dA5waxvJknYDxwtYnIcQ/132, createdBy=294e2500218, createdName=ms3046638856685384, createdTime=Thu Sep 27 09:54:00 CST 2018, time=2018-09-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1427246, encodeId=dca8142e2469f, content=<a href='/topic/show?id=221d685172' target=_blank style='color:#2F92EE;'>#EPA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6851, encryptionId=221d685172, topicName=EPA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4a9b4077760, createdName=gwc384, createdTime=Thu Sep 27 09:54:00 CST 2018, time=2018-09-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1581160, encodeId=c0de158116098, content=<a href='/topic/show?id=d40b423548' target=_blank style='color:#2F92EE;'>#CCR5抑制剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4235, encryptionId=d40b423548, topicName=CCR5抑制剂)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=843916719849, createdName=12498aa2m67(暂无昵称), createdTime=Thu Sep 27 09:54:00 CST 2018, time=2018-09-27, status=1, ipAttribution=)]
    2019-05-08 jklm09
  2. [GetPortalCommentsPageByObjectIdResponse(id=1851793, encodeId=126c1851e93c0, content=<a href='/topic/show?id=f0a254918f0' target=_blank style='color:#2F92EE;'>#抑制剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54918, encryptionId=f0a254918f0, topicName=抑制剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=44a360, createdName=jklm09, createdTime=Wed May 08 15:54:00 CST 2019, time=2019-05-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1977730, encodeId=6c2919e7730c2, content=<a href='/topic/show?id=4b7d4230bd' target=_blank style='color:#2F92EE;'>#CCR2#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4230, encryptionId=4b7d4230bd, topicName=CCR2)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=08e4137, createdName=meichuangyi, createdTime=Sun May 12 22:54:00 CST 2019, time=2019-05-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1338791, encodeId=a2ac1338e9190, content=<a href='/topic/show?id=9d3d812280b' target=_blank style='color:#2F92EE;'>#肝损伤#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=81228, encryptionId=9d3d812280b, topicName=肝损伤)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=198d2500149, createdName=12498bd5m16暂无昵称, createdTime=Thu Sep 27 09:54:00 CST 2018, time=2018-09-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1397630, encodeId=e4d0139e6308e, content=<a href='/topic/show?id=8bee565436d' target=_blank style='color:#2F92EE;'>#损伤#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=56543, encryptionId=8bee565436d, topicName=损伤)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/DYAIOgq83eoNX3lUOlDKGBUEPNwZx0nibmdcFyeibnX4WMhUSCU2REpGRWtSmnT2CCs0dA5waxvJknYDxwtYnIcQ/132, createdBy=294e2500218, createdName=ms3046638856685384, createdTime=Thu Sep 27 09:54:00 CST 2018, time=2018-09-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1427246, encodeId=dca8142e2469f, content=<a href='/topic/show?id=221d685172' target=_blank style='color:#2F92EE;'>#EPA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6851, encryptionId=221d685172, topicName=EPA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4a9b4077760, createdName=gwc384, createdTime=Thu Sep 27 09:54:00 CST 2018, time=2018-09-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1581160, encodeId=c0de158116098, content=<a href='/topic/show?id=d40b423548' target=_blank style='color:#2F92EE;'>#CCR5抑制剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4235, encryptionId=d40b423548, topicName=CCR5抑制剂)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=843916719849, createdName=12498aa2m67(暂无昵称), createdTime=Thu Sep 27 09:54:00 CST 2018, time=2018-09-27, status=1, ipAttribution=)]
    2019-05-12 meichuangyi
  3. [GetPortalCommentsPageByObjectIdResponse(id=1851793, encodeId=126c1851e93c0, content=<a href='/topic/show?id=f0a254918f0' target=_blank style='color:#2F92EE;'>#抑制剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54918, encryptionId=f0a254918f0, topicName=抑制剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=44a360, createdName=jklm09, createdTime=Wed May 08 15:54:00 CST 2019, time=2019-05-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1977730, encodeId=6c2919e7730c2, content=<a href='/topic/show?id=4b7d4230bd' target=_blank style='color:#2F92EE;'>#CCR2#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4230, encryptionId=4b7d4230bd, topicName=CCR2)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=08e4137, createdName=meichuangyi, createdTime=Sun May 12 22:54:00 CST 2019, time=2019-05-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1338791, encodeId=a2ac1338e9190, content=<a href='/topic/show?id=9d3d812280b' target=_blank style='color:#2F92EE;'>#肝损伤#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=81228, encryptionId=9d3d812280b, topicName=肝损伤)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=198d2500149, createdName=12498bd5m16暂无昵称, createdTime=Thu Sep 27 09:54:00 CST 2018, time=2018-09-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1397630, encodeId=e4d0139e6308e, content=<a href='/topic/show?id=8bee565436d' target=_blank style='color:#2F92EE;'>#损伤#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=56543, encryptionId=8bee565436d, topicName=损伤)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/DYAIOgq83eoNX3lUOlDKGBUEPNwZx0nibmdcFyeibnX4WMhUSCU2REpGRWtSmnT2CCs0dA5waxvJknYDxwtYnIcQ/132, createdBy=294e2500218, createdName=ms3046638856685384, createdTime=Thu Sep 27 09:54:00 CST 2018, time=2018-09-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1427246, encodeId=dca8142e2469f, content=<a href='/topic/show?id=221d685172' target=_blank style='color:#2F92EE;'>#EPA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6851, encryptionId=221d685172, topicName=EPA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4a9b4077760, createdName=gwc384, createdTime=Thu Sep 27 09:54:00 CST 2018, time=2018-09-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1581160, encodeId=c0de158116098, content=<a href='/topic/show?id=d40b423548' target=_blank style='color:#2F92EE;'>#CCR5抑制剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4235, encryptionId=d40b423548, topicName=CCR5抑制剂)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=843916719849, createdName=12498aa2m67(暂无昵称), createdTime=Thu Sep 27 09:54:00 CST 2018, time=2018-09-27, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1851793, encodeId=126c1851e93c0, content=<a href='/topic/show?id=f0a254918f0' target=_blank style='color:#2F92EE;'>#抑制剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54918, encryptionId=f0a254918f0, topicName=抑制剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=44a360, createdName=jklm09, createdTime=Wed May 08 15:54:00 CST 2019, time=2019-05-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1977730, encodeId=6c2919e7730c2, content=<a href='/topic/show?id=4b7d4230bd' target=_blank style='color:#2F92EE;'>#CCR2#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4230, encryptionId=4b7d4230bd, topicName=CCR2)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=08e4137, createdName=meichuangyi, createdTime=Sun May 12 22:54:00 CST 2019, time=2019-05-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1338791, encodeId=a2ac1338e9190, content=<a href='/topic/show?id=9d3d812280b' target=_blank style='color:#2F92EE;'>#肝损伤#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=81228, encryptionId=9d3d812280b, topicName=肝损伤)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=198d2500149, createdName=12498bd5m16暂无昵称, createdTime=Thu Sep 27 09:54:00 CST 2018, time=2018-09-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1397630, encodeId=e4d0139e6308e, content=<a href='/topic/show?id=8bee565436d' target=_blank style='color:#2F92EE;'>#损伤#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=56543, encryptionId=8bee565436d, topicName=损伤)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/DYAIOgq83eoNX3lUOlDKGBUEPNwZx0nibmdcFyeibnX4WMhUSCU2REpGRWtSmnT2CCs0dA5waxvJknYDxwtYnIcQ/132, createdBy=294e2500218, createdName=ms3046638856685384, createdTime=Thu Sep 27 09:54:00 CST 2018, time=2018-09-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1427246, encodeId=dca8142e2469f, content=<a href='/topic/show?id=221d685172' target=_blank style='color:#2F92EE;'>#EPA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6851, encryptionId=221d685172, topicName=EPA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4a9b4077760, createdName=gwc384, createdTime=Thu Sep 27 09:54:00 CST 2018, time=2018-09-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1581160, encodeId=c0de158116098, content=<a href='/topic/show?id=d40b423548' target=_blank style='color:#2F92EE;'>#CCR5抑制剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4235, encryptionId=d40b423548, topicName=CCR5抑制剂)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=843916719849, createdName=12498aa2m67(暂无昵称), createdTime=Thu Sep 27 09:54:00 CST 2018, time=2018-09-27, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=1851793, encodeId=126c1851e93c0, content=<a href='/topic/show?id=f0a254918f0' target=_blank style='color:#2F92EE;'>#抑制剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54918, encryptionId=f0a254918f0, topicName=抑制剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=44a360, createdName=jklm09, createdTime=Wed May 08 15:54:00 CST 2019, time=2019-05-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1977730, encodeId=6c2919e7730c2, content=<a href='/topic/show?id=4b7d4230bd' target=_blank style='color:#2F92EE;'>#CCR2#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4230, encryptionId=4b7d4230bd, topicName=CCR2)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=08e4137, createdName=meichuangyi, createdTime=Sun May 12 22:54:00 CST 2019, time=2019-05-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1338791, encodeId=a2ac1338e9190, content=<a href='/topic/show?id=9d3d812280b' target=_blank style='color:#2F92EE;'>#肝损伤#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=81228, encryptionId=9d3d812280b, topicName=肝损伤)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=198d2500149, createdName=12498bd5m16暂无昵称, createdTime=Thu Sep 27 09:54:00 CST 2018, time=2018-09-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1397630, encodeId=e4d0139e6308e, content=<a href='/topic/show?id=8bee565436d' target=_blank style='color:#2F92EE;'>#损伤#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=56543, encryptionId=8bee565436d, topicName=损伤)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/DYAIOgq83eoNX3lUOlDKGBUEPNwZx0nibmdcFyeibnX4WMhUSCU2REpGRWtSmnT2CCs0dA5waxvJknYDxwtYnIcQ/132, createdBy=294e2500218, createdName=ms3046638856685384, createdTime=Thu Sep 27 09:54:00 CST 2018, time=2018-09-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1427246, encodeId=dca8142e2469f, content=<a href='/topic/show?id=221d685172' target=_blank style='color:#2F92EE;'>#EPA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6851, encryptionId=221d685172, topicName=EPA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4a9b4077760, createdName=gwc384, createdTime=Thu Sep 27 09:54:00 CST 2018, time=2018-09-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1581160, encodeId=c0de158116098, content=<a href='/topic/show?id=d40b423548' target=_blank style='color:#2F92EE;'>#CCR5抑制剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4235, encryptionId=d40b423548, topicName=CCR5抑制剂)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=843916719849, createdName=12498aa2m67(暂无昵称), createdTime=Thu Sep 27 09:54:00 CST 2018, time=2018-09-27, status=1, ipAttribution=)]
    2018-09-27 gwc384
  6. [GetPortalCommentsPageByObjectIdResponse(id=1851793, encodeId=126c1851e93c0, content=<a href='/topic/show?id=f0a254918f0' target=_blank style='color:#2F92EE;'>#抑制剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54918, encryptionId=f0a254918f0, topicName=抑制剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=44a360, createdName=jklm09, createdTime=Wed May 08 15:54:00 CST 2019, time=2019-05-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1977730, encodeId=6c2919e7730c2, content=<a href='/topic/show?id=4b7d4230bd' target=_blank style='color:#2F92EE;'>#CCR2#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4230, encryptionId=4b7d4230bd, topicName=CCR2)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=08e4137, createdName=meichuangyi, createdTime=Sun May 12 22:54:00 CST 2019, time=2019-05-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1338791, encodeId=a2ac1338e9190, content=<a href='/topic/show?id=9d3d812280b' target=_blank style='color:#2F92EE;'>#肝损伤#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=81228, encryptionId=9d3d812280b, topicName=肝损伤)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=198d2500149, createdName=12498bd5m16暂无昵称, createdTime=Thu Sep 27 09:54:00 CST 2018, time=2018-09-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1397630, encodeId=e4d0139e6308e, content=<a href='/topic/show?id=8bee565436d' target=_blank style='color:#2F92EE;'>#损伤#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=56543, encryptionId=8bee565436d, topicName=损伤)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/DYAIOgq83eoNX3lUOlDKGBUEPNwZx0nibmdcFyeibnX4WMhUSCU2REpGRWtSmnT2CCs0dA5waxvJknYDxwtYnIcQ/132, createdBy=294e2500218, createdName=ms3046638856685384, createdTime=Thu Sep 27 09:54:00 CST 2018, time=2018-09-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1427246, encodeId=dca8142e2469f, content=<a href='/topic/show?id=221d685172' target=_blank style='color:#2F92EE;'>#EPA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6851, encryptionId=221d685172, topicName=EPA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4a9b4077760, createdName=gwc384, createdTime=Thu Sep 27 09:54:00 CST 2018, time=2018-09-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1581160, encodeId=c0de158116098, content=<a href='/topic/show?id=d40b423548' target=_blank style='color:#2F92EE;'>#CCR5抑制剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4235, encryptionId=d40b423548, topicName=CCR5抑制剂)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=843916719849, createdName=12498aa2m67(暂无昵称), createdTime=Thu Sep 27 09:54:00 CST 2018, time=2018-09-27, status=1, ipAttribution=)]

相关资讯

Hepatology:Cenicriviroc治疗非酒精性脂肪性肝炎相关肝纤维化的随机、安慰剂对照试验

CVC治疗1年后,相比安慰剂对照组,两倍的患者肝纤维化得到改善,并且非酒精性脂肪性肝炎没有恶化。Cenicriviroc所展现出的抗纤维化作用值得进一步关注。

Cenicriviroc能改善非酒精性脂肪肝炎患者的纤维化情况,且不会导致脂肪性肝炎恶化

2016年肝病会议上呈现的CENTAUR研究数据显示,Cenicriviroc治疗1年,可以改善非酒精性脂肪肝炎(NASH)患者的纤维化情况,且不伴有脂肪性肝炎的恶化。不过目前呈现的研究数据没有达到其主要终点。 来自弗吉尼亚州立大学的Arun J. Sanyal博士称:“CENTAUR研究的目的是,评估CVC [cenicriviroc] 150 mg 治疗2年的有效性和安全性。这是一个正在